Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic

British Journal of Dermatology

Volumn 172, Issue 4, 2015, Pages 861-866

  Burden Teh, E ^a,b   Wootton, C I ^a   Williams, H C ^a,b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE; PAROMOMYCIN; AMINOGLYCOSIDE; ANTIPROTOZOAL AGENT; PHOSPHORYLCHOLINE; WR279396;

AFGHANISTAN; ARTICLE; CASE REPORT; CHILD; COCHRANE LIBRARY; DISEASE DURATION; EMBASE; HUMAN; INFLAMMATORY INFILTRATE; LEISHMANIA TROPICA; MALE; MEDLINE; OUTPATIENT CARE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RURAL POPULATION; SCAR FORMATION; SKIN BIOPSY; SKIN DEFECT; SKIN EXAMINATION; SKIN GRANULOMA; SKIN LEISHMANIASIS; TREATMENT DURATION; TREATMENT RESPONSE; AMBULATORY CARE; ANALOGS AND DERIVATIVES; INTRADERMAL DRUG ADMINISTRATION; LEISHMANIASIS, CUTANEOUS; PROCEDURES;

ADMINISTRATION, CUTANEOUS; AMBULATORY CARE; AMINOGLYCOSIDES; ANTIPROTOZOAL AGENTS; CHILD, PRESCHOOL; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; PAROMOMYCIN; PHOSPHORYLCHOLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84943589401     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13496     Document Type: Article

References (11)

1. Alvar J, Vélez ID, Bern C, et al,. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671.
2. González U, Pinart M, Rengifo-Pardo M, et al,. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009; CD004834.
3. González U, Pinart M, Reveiz L, Alvar J,. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008; CD005067.
4. Murray HW, Berman JD, Davies CR, Saravia NG,. Advances in leishmaniasis. Lancet 2005; 366: 1561-77.
5. Ben Salah A, Buffet PA, Morizot G, et al,. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009; 3: e432.
6. Ben Salah SA, Ben Messaoud N, Guedri E, et al,. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368: 524-32.
7. Rubiano LC, Miranda MC, Muvdi Arenas S, et al,. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012; 205: 684-92.
8. Machado PR, Ampuero J, Guimarães LH, et al,. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010; 4: e912.
9. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, et al,. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84: 255-60.
10. Asilian A, Jalayer T, Nilforooshzadeh M, et al,. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003; 81: 353-9.
11. Olliaro P, Vaillant M, Arana B, et al,. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 2013; 7: e2130.